Anti Fungal Drug

Phase 3Small molecule

UUniversity of California, San Francisco

Anti Fungal Drug is one of 9 small molecule programs targeting Corneal Ulcer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Corneal UlcerActive, not recruiting

Corneal UlcerPhase 3

Active, not recruiting

Competition

Competitive Landscape

17 competitors in Corneal Ulcer

#DrugCompanyPhaseTrials

Levaquin

WWim Janssens

Approved

—2

Antibiotics

MMelinta Therapeutics, Inc.

Approved

1 3

Betadine

BBecton, Dickinson and Company

Phase 2

1 4

Vfend

PPrism Pharmaceuticals

Phase 2

1 5

Natacyn

HHarrow Inc

Phase 3

2 6

Anti Fungal Drug

UUniversity of California, San Francisco

Phase 3

1 7

Riboflavin

CCornea and Laser Eye Institute

Phase 1

—8

Naltrexone Hydrochloride

EEnsysce Biosciences

Preclinical

1 9

Specific Treatment

AAssistance Publique - Hôpitaux de Paris

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Corneal Ulcer1 trial

Cross-linking for Corneal Ulcers Treatment Trial

Completed·UUniversity of California, San Francisco·Phase 3·NCT02570321·147 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Anti Fungal Drug. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anti Fungal Drug compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anti Fungal Drug. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, San Francisco company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of California, San Francisco

Anti Fungal Drug

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Corneal Ulcer1 trial

References

Drug Info

Quick Facts

Related News